Literature DB >> 28638252

Evaluation of the Ki-67 Proliferation Index and Urocortin Expression in Women with Ovarian Endometriomas.

Serenat Eris Yalcin1, Irfan Ocal2, Yakup Yalcin3, Halime Sen Selim4, Melike Demir Caltekin5, Huseyin Aydogmus6, Sefa Kelekci7.   

Abstract

OBJECTIVE: The reasons why endometriosis is more aggressive and invasive in some patients are unknown. Despite the importance of population-based clinically defined risk factors in the prediction of recurrence, biochemical markers obtained from the patient are more valuable for prediction on an individual basis. Therefore, the discovery of significant potential biomarkers could be useful to clinicians for shedding light on the pathogenesis of endometriosis and in the monitoring recurrence.
MATERIALS AND METHODS: This study included 50 patients who underwent surgery for ovarian cysts that were diagnosed as endometrioma. The age of the patients, stage of the endometriosis, diameter and localization of endometriomas, type of surgery, and pre- and postoperative cancer antigen 125 (CA125) levels were compared between patients with and without recurrence. The archived pathology slides were stained with Ki-67 and anti-urocortin antibodies for reevaluation. By comparing the pathology parameters of the patients with and without recurrence, the association between these parameters and recurrence was investigated.
RESULTS: The median Ki-67 proliferation index of the patients with recurrence (7.5±6.5) was statistically significant compared with that of the patients without recurrence (1±4) (p=0.003). The urocortin epithelial staining intensity and percentage were not found to be statistically significant in comparison. A statistically significant difference was determined between postoperative CA125 median levels of patients without recurrence (10±17.6) and those of patients with recurrence (29.9±18.1) (p=0.003).
CONCLUSION: The Ki-67 proliferation index may be useful for predicting prognosis and recurrence risk.

Entities:  

Keywords:  Endometriosis; Ki-67 proliferation index; urocortin

Year:  2017        PMID: 28638252      PMCID: PMC5469835          DOI: 10.5152/eurasianjmed.2017.17070

Source DB:  PubMed          Journal:  Eurasian J Med        ISSN: 1308-8734


  21 in total

1.  Identification of urocortin mRNA and peptide in the human endometrium.

Authors:  P Florio; F Arcuri; P Ciarmela; Y Runci; R Romagnoli; M Cintorino; A M Di Blasio; F Petraglia
Journal:  J Endocrinol       Date:  2002-05       Impact factor: 4.286

2.  Impaired CRH and urocortin expression and function in eutopic endometrium of women with endometriosis.

Authors:  Romina Novembri; Lavinia Estrela Borges; Patrizia Carrarelli; Ana Luiza Lunardi Rocha; Flavio De Pascalis; Pasquale Florio; Felice Petraglia
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

3.  Immunohistochemical analysis of CA125, CA19-9, and Ki-67 in stage III or IV endometriosis: positive correlation between serum CA125 level and endometriotic epithelial cell proliferation.

Authors:  T Toki; J Kubota; X Lu; K Nakayama
Journal:  Acta Obstet Gynecol Scand       Date:  2000-09       Impact factor: 3.636

4.  Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor.

Authors:  K Lewis; C Li; M H Perrin; A Blount; K Kunitake; C Donaldson; J Vaughan; T M Reyes; J Gulyas; W Fischer; L Bilezikjian; J Rivier; P E Sawchenko; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

5.  Serum CA 125 measurements in the diagnosis of endometriosis recurrence.

Authors:  L Fedele; L Arcaini; P Vercellini; S Bianchi; G B Candiani
Journal:  Obstet Gynecol       Date:  1988-07       Impact factor: 7.661

6.  Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors.

Authors:  T M Reyes; K Lewis; M H Perrin; K S Kunitake; J Vaughan; C A Arias; J B Hogenesch; J Gulyas; J Rivier; W W Vale; P E Sawchenko
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

7.  Apoptosis, proliferation, and sex hormone receptors in superficial parts of human endometrium at the end of the secretory phase.

Authors:  M Dahmoun; K Boman; S Cajander; P Westin; T Bäckström
Journal:  J Clin Endocrinol Metab       Date:  1999-05       Impact factor: 5.958

8.  Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor.

Authors:  J Vaughan; C Donaldson; J Bittencourt; M H Perrin; K Lewis; S Sutton; R Chan; A V Turnbull; D Lovejoy; C Rivier
Journal:  Nature       Date:  1995-11-16       Impact factor: 49.962

9.  Cholesteatoma epithelium is characterized by increased expression of Ki-67, p53 and p21, with minimal apoptosis.

Authors:  Margriet A Huisman; Emile De Heer; Jan J Grote
Journal:  Acta Otolaryngol       Date:  2003-04       Impact factor: 1.494

10.  CA 125 levels in monitoring therapy for endometriosis and in prediction of recurrence.

Authors:  M Nagamani; M E Kelver; E R Smith
Journal:  Int J Fertil       Date:  1992 Jul-Aug
View more
  3 in total

1.  MiR-520d-3p antitumor activity in human breast cancer via post-transcriptional regulation of spindle and kinetochore associated 2 expression.

Authors:  Zhouhui Ren; Tong Yang; Jie Ding; Weihong Liu; Xiangyu Meng; Pingping Zhang; Kaitai Liu; Ping Wang
Journal:  Am J Transl Res       Date:  2018-04-15       Impact factor: 4.060

2.  Prognostic importance of atypical endometriosis with architectural hyperplasia versus cytologic atypia in endometriosis-associated ovarian cancer.

Authors:  Isabel Ñiguez Sevilla; Francisco Machado Linde; Maria Del Pilar Marín Sánchez; Julián Jesús Arense; Amparo Torroba; Anibal Nieto Díaz; Maria Luisa Sánchez Ferrer
Journal:  J Gynecol Oncol       Date:  2019-03-04       Impact factor: 4.401

3.  Augmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: an up-dated systematic review and meta-analysis with 108 studies and 14,732 patients.

Authors:  Dan-Ming Wei; Wen-Jie Chen; Rong-Mei Meng; Na Zhao; Xiang-Yu Zhang; Dan-Yu Liao; Gang Chen
Journal:  Respir Res       Date:  2018-08-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.